Chinese COVID-19 vaccine Ad5-Ncov shows high antibody levels at Russian trial -Ifax


FILE PHOTO: Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. China Daily via REUTERS

MOSCOW (Reuters) - Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.

Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit.

(Reporting by Alexander Marrow; editing by John Stonestreet)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

73% readers found this article insightful

Next In World

New COVID-19 variant defeats plasma treatment, may reduce vaccine efficacy
British stocks up 0.41 pct Wednesday
German shares gain 0.77 pct Wednesday
Portugal experiences worst day of COVID-19 pandemic
3rd LD-Writethru-Xinhua Headlines-Xi Focus: Xi stresses advancing Beijing 2022 preparation with perfection
Lebanon reports highest daily COVID-19 deaths for 2nd consecutive day
Indian government offers to suspend farm reforms; farmers may call off protests
Kremlin critic Alexei Navalny held in infamous Moscow jail
Newsmaker: Kamala Harris breaks barriers as America's vice president
Biden to hit reset on nation's fight against COVID-19 on his first day as president

Stories You'll Enjoy